Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.68 |
| ▸ | MAOA | P21397 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EDNRB | P24530 | 1/20 | 0.51 |
| ▸ | EDNRA | P25101 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984460 | 0.93 | MAOB (0.68) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL22221556 | 0.90 | MAOB (0.64) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL13534204 | 0.89 | MAOB (0.68) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL107322 | 0.89 | MAOB (0.83) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL14382267 | 0.88 | MAOB (0.62) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL108114 | 0.87 | MAOB (0.74) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL13534217 | 0.86 | MAOB (0.59) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL1276632 | 0.85 | MAOB (0.66) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL984344 | 0.85 | MAOB (0.62) | MAOBMAOARAB9ANPC1MAPT | |
| SCHEMBL11802724 | 0.85 | MAOB (0.72) | MAOBMAOARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102892492-A | Delivery particle | PROCTER & GAMBLE | 2013-01-23 | — | — | CN | claimed |
| CN-102892492-B | Delivery of particles | THE PROCTER & GAMBLE CO. (US) | 2016-02-24 | — | — | CN | disclosed |
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| CN-102892492-A | Delivery particle | PROCTER & GAMBLE | 2013-01-23 | — | — | CN | disclosed |
| CN-102858944-A | Delivery particles | PROCTER & GAMBLE | 2013-01-02 | — | — | CN | disclosed |
| US-8217119-B2 | Additives for halopolymers | SOLVAY SOLEXIS S.P.A. (IT) | 2012-07-10 | — | — | US | disclosed |
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | COLUCID PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1319007-B9 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | TACR2, NPSR1, TACR3 | MAOB 703/4885MAOA 476/4885RAB9A 1414/4885 |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | MAOB 156/4885MAOA 192/4885RAB9A 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.